Microbix Presenting at Muskoka Capital Conference
29 September 2023 - 9:00PM
Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that it will be presenting to investors at the
Muskoka Capital Conference, organized by Capital Event Management
Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in
Minett, Ontario, September 29 to October 1, 2023.
Microbix’s CEO, Cameron Groome, and SVP, Sales
and Business Development, Phil Casselli, will undertake a series of
18 one-on-one meetings with growth company investors during the
formal portion of the conference. The presentation slides to which
they will be speaking will be posted to the Microbix website at
https://microbix.com, along with other business information and its
financial disclosures.
About Microbix
BiosystemsMicrobix develops proprietary biological
products for human health, with over 100 skilled employees and
sales now targeting C$ 2.0 million per month. It makes a wide range
of critical ingredients and devices for the global diagnostics
industry, notably antigens for immunoassays and its laboratory
quality assessment products (QAPs™ IVD or RUO test-controls) that
support clinical lab proficiency testing, enable assay development
and validation, or help ensure the quality of clinical diagnostic
workflows. Microbix antigens enable the antibody tests of
approximately 100 diagnostics makers, while QAPs are sold to
clinical lab accreditation organizations, diagnostics companies,
and clinical laboratories. Microbix QAPs are now available in over
30 countries, supported by a network of international distributors.
Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered,
Australian TGA registered, Health Canada establishment licensed,
and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
About Capital Event Management Ltd. and
the EventCapital Event Management Ltd. produces multiple
investor events each year, across North America and in the Bahamas.
Attendees include leading public and private companies, and a range
of investors consisting of investment advisors, fund managers, and
high net worth investors. Capital Event’s unique event formats aim
to allow principals to establish new and lasting relationships that
lead to financings, open market support, and increased awareness
within the investment community. Further information about the
Muskoka event is available at
https://cem.ca/conference/muskoka-capital-event/
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of Capital
Event Management Ltd. and its conferences, Microbix’s business and
business results, goals or outlook, risks associated with financial
results and stability, development projects such as those
referenced in its corporate presentation, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity and timeliness of delivery),
foreign currency and exchange rates, maintaining profitability and
adequate working capital, or raising further capital on acceptable
terms or at all, and other similar statements concerning
anticipated future events, conditions or results that are not
historical facts. These statements reflect management’s current
estimates, beliefs, intentions and expectations; they are not
guarantees of future performance. The Company cautions that all
forward looking information is inherently uncertain and that actual
performance may be affected by a number of material factors, many
of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from
the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit www.microbix.com or www.sedar.com for
recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
|
|
|
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024